195
Participants
Start Date
October 8, 2021
Primary Completion Date
May 16, 2026
Study Completion Date
August 31, 2026
LUNA18
LUNA18 Capsule
Cetuximab
Cetuximab as a IV infusion
Icahn School of Medicine at Mount Sinai, New York
Abramson Cancer Center at Pennsylvania Hospital, Philadelphia
NEXT Virginia, Fairfax
Barbara Ann Karmanos Cancer Institute, Detroit
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
University of Wisconsin - Carbone Cancer Center, Madison
MD Anderson Cancer Center, Houston
NEXT Oncology, Austin
Renown Regional Medical Center, Reno
University of California - Davis, Davis
Beth Israel Deaconess, Boston
Dana-Farber Cancer Institute, Boston
Rhode Island Hospital-Comprehensive Cancer Center, Providence
Aichi Cancer Center, Nagoya
National Cancer Center Hospital East, Kashiwa
Shizuoka Cancer Center, Nakatogari
National Cancer Center Hospital, Chuo-Ku
The Cancer Institute Hospital of JFCR, Koto-ku
National Hospital Organization Kyushu Cancer Center, Fukuoka
Osaka International Cancer Institute, Osaka
Lead Sponsor
Chugai Pharmaceutical
INDUSTRY